Taken together, our results, support the existing body of literature characterizing BRCA1 and BRCA2 mutations as predictive of chemo‐response and potentially associated with high tumor immune cell infiltration and PD‐L1 IHC expression. The gene discussed is BRCA1; the disease is neoplasm.